...OUTPERFORM NOVARTIS Switzerland – Market price at 11/30/2015 closing price: $90.43 DEVAUX Paul, MÉAR Germain – 11/03/2015 Activities: Novartis is the number one pharmaceutical company in the world regarding sales: $47,101 million in 2014. Its headquarters are in Basel, in Switzerland. This company was born from the merger of Ciba-Geigy and Sandoz in 1996. Those companies are both Swiss company with a great history in this sector. The merger of J.R GEIGY LTD and CIBA also formed Ciba-Geigy. Those both companies were founded in Basel In 1758 and 1859. Novartis famous drugs are: • Clozapine (Clozaril) used in the treatment of schizophrenia • Diclofenac (Voltaren) used to reduce inflammation • Pharmaceutical Industry Sector Extreme (52w)) Lowest $88.89 Highest $107.1 Latest price $91.04 Vaksartan (Diovan) used to treat high blood pressure Novartis focused first on its pharmaceutical and agrochemical activities and sold other businesses. Novartis is operating directly and through dozens of subsidiaries in countries around the world. There are three key divisions in Novartis: Pharmaceuticals, Alcon and Sandoz. Its pharmaceuticals division aims at providing innovative and important medicines for health needs. It has a portfolio of over sixty medicines, which often are leaders in their therapeutic areas. In addition, this division is currently working on more than...
Words: 3850 - Pages: 16
...Global Talent Management at Novartis Novartis is one of the largest pharmaceutical companies in the world that spans across 140 countries. Daniel Vasella, CEO, has transformed Novartis into a 100% healthcare company by ridding the company of its specialty chemicals business. By doing so, Novartis became the second largest producer of generic drugs. Vasella reconstructed the company’s approach towards global talent management since the previous approach lacked regular performance review, global objectives, and incentive based pays as a deterrent of motivation. Vasella implemented a universal performance management system and new culture, which is based on candor, performance, and accountability. The key issue involves contradictions with Novartis’s past culture and Vasella’s new culture. The new list of values and behaviors lacks cultural sensitivity and does not reflect the culture that has developed at Novartis. Vasella must implement a plan that includes values and behaviors that are adaptable and based on local cultures to minimize ethnocentrism. Through contingency management, this goal may be achieved because this concept uses management tools and techniques in a situational appropriate behavior, which will avoid the one-best-way mentality. Vasella’s new list of values and behaviors may include: be productive, be innovative, be proactive, be accountable, and be respectful. Top performing companies are more likely to have performance-based rewards, so Vasella should...
Words: 303 - Pages: 2
...markets and international competition are increasing the amount of diversity organizations must manage, both internally and externally. Diversity specialists (Soutar, 2004; Yang, 2005) have suggested in that in order for businesses and organizations interested in prospering and surviving in the twenty-first century embracing the competitive advantage afforded by a diverse workplace is needed This report looks at the impact of managing diversity in the workplace and the performance and financial benefits which can be gained from successful management. Novartis Pharmaceuticals is one such company which has placed emphasis on embracing and managing diversity and using this to the company’s advantage. The Company Novartis is a global healthcare company founded in 1996 headquarted in Basel Switzerland with a presence in 140 countries providing medical solutions to the evolving needs of patients worldwide (Novartis.com, 2015). Novartis International AG employs approximately 135,696 employees and is also, ranked number one in sales earning US 58.4 billion in 2014. (Wikipedia.com, 2015). The company produces...
Words: 2250 - Pages: 9
...Fremont Canning Company, which produced canned fruit and vegetables. At the suggestion of a pediatrician, Gerber's wife Dorothy Gerber began making hand-strained food for their seven-month-old daughter, Sally. Recognising a business opportunity, Gerber began making baby food. By 1928 he had developed five products for the market and six months later, Gerber's baby foods were distributed nationwide. The brand eventually became a major company in the baby food industry, offering more than 190 products in 80 countries, with labeling in 16 languages and controls eighty-three percent (83%) of the baby food market in the United States. In 1994 Gerber merged with Sandoz Laboratories. Two years later, Sandoz merged with CIBA-Geigy to form Novartis, one of the largest pharmaceutical companies in the world. In 2007 Gerber was sold to Nestle for $5.5 billion. In 1960 Gerber started selling its baby food in glass jars, which often found new life as household storage, especially in home workshops. Soon after, other items such as pacifiers, , baby bottles, and small baby toys were introduced. Source: https://en.wikipedia.org/wiki/Gerber_Products_Company B. Problem Encountered and Quamet Solution Used or Applied Gerber used decision tree analysis in deciding whether to continue using the plastic known as poly-vinyl chloride or, more commonly, PVC. Gerber management had to evaluate all of the current information, weigh the consequences of each action, and proceed on the...
Words: 834 - Pages: 4
...The Pharmaceutical Industry 1. Origins and Evolution The modern pharmaceutical industry is a highly competitive non-assembled1 global industry. Its origins can be traced back to the nascent chemical industry of the late nineteenth century in the Upper Rhine Valley near Basel, Switzerland when dyestuffs were found to have antiseptic properties. A host of modern pharmaceutical companies all started out as Rhine-based family dyestuff and chemical companies e.g. Hoffman-La Roche, Sandoz, Ciba-Geigy (the product of a merger between Ciba and Geigy), Novartis2 etc. Most are still going strong today3. Over time many of these chemical companies moved into the production of pharmaceuticals and other synthetic chemicals and they gradually evolved into global players. The introduction and success of penicillin in the early forties and the relative success of other innovative drugs, institutionalized research and development (R&D) efforts in the industry 4. The industry expanded rapidly in the sixties, benefiting from new discoveries and a lax regulatory environment. During this period healthcare spending boomed as global economies prospered. The industry witnessed major developments in the seventies with the introduction of tighter regulatory controls, especially with the introduction of regulations governing the manufacture of ‘generics’5. The new regulations revoked permanent patents and established fixed periods on patent protection for branded products, a result of...
Words: 1706 - Pages: 7
...these products and that means someone somewhere is having an increase in profits. Perhaps pharmaceuticals aren't the next .com bubble, but taking a look at some of the biggest firms might be useful for a budding portfolio manager. This article will look at the three biggest pharma companies, and next weeks article will look at some of the most promising start up pharma companies. The three biggest companies in the world according to Forbes are: Pfizer, Novartis, Sanofi respectively. Pfizer is the largest pharmaceutical company in the world and has posted fairly steady gains over the last three years (Forbes, Bloomberg, Morningstar). According to Peter Lynch in his book “One Up On Wall Street,” this company would be an example of a stalwart (Peter Lynch 'One up on Wall Street'). That means that this company will not give you huge returns, but will provide consistent returns with relatively low volatility. Pfizer is perhaps the most well known of pharmaceutical stock options, but it might not necessarily be the best of options. Novartis has had similar amounts of revenue, but has had less goodwill and long-term debt (Morningstar). Knowing what to look for in a company is sometimes tricky, and I won't pretend to be the best portfolio manager in the world, but there are a few things in Pfizers' financials...
Words: 576 - Pages: 3
...UNIFORM CODE OF PHARMACEUTICAL MARKETING PRACTICES The Indian Pharmaceutical Industry is one of the most rapidly growing science based industries in terms of remarkable capabilities in both the manufacture and technology. India being among one of the five pharmaceutical emerging markets has an average annual growth of 8-9 percent with an approximate worth of $ 4.5 billion. With more new drug launches, new drug applications, phase II clinical trials taking place this year the growth can be expected to be 13-14 percent in the future. Considering the rise in the pharmaceutical sector and to bring about uniformity in the marketing of these drugs, a Code has been introduced by the Department of Pharmaceuticals (DoP), Government of India. This code named as Uniform Code of Pharmaceutical Marketing Practices (UCPMP) was introduced on December 12, 2014 and became effective from January 01, 2015. UCPMP initially set to be a voluntary code for the Pharmaceutical Industries was then decided to be made as statutory Code when DoP was urged by the Organization of Pharmaceutical Producers of India (OPPI). UCPMP is expected to facilitate good marketing practices, increased levels of transparency and accountability across healthcare industry and remove ambiguity on all aspects of marketing by the pharmaceutical industries. The code covers various parameters like the general points to be followed by the industry, claims and comparisons related to other products, textual and audiovisual...
Words: 1441 - Pages: 6
...ASSIGNMENT ON OPERATION RESEARCH ( FIN – 3104 ) 3RD YEAR , 1ST SEMESTER BBA – 3RD BATCH DEPARTMENT OF FINANCE JAGANNATH UNIVERSITY TOPIC Quantitative Analysis for Optimization : Using Linear Programming & Transportation Problem Group Name Name & ID No. of the Group Members: |Sl. No. |Name |ID No. | | | | | |01 |Suman Chandra Mandal (Group Leader) |091557 | | |Md. Nahid Islam |091604 | |02 | | | | | | | |03 |Mahbuba Mehreen |091619 ...
Words: 1940 - Pages: 8
...Abstract The aim of the study is to present the current scenario of the pharmaceutical industry in Bangladesh. In Bangladesh, the pharmaceutical sector is one of the most developed hi-tech sectors, which is contributing in the country’s economy. After promulgation of Drug Control Ordinance -1982, the development of this sector was accelerated. The professional knowledge, thoughts and innovative ideas of the pharmaceutical professionals working in this sector are the key factors for this development. Due to resent development of this sector, it is exporting medicines to global markets including highly regulated European markets. This sector also providing 97% of the total medicine requirement of the local market. Leading pharmaceutical companies are expanding their business with the aim to expand export market recently few new companies have been established with hi-tech equipments and high professionals which will enhance the strength of this sector. Government declared “Pharmaceuticals as the product of the year (2008), in a bid to boost it export further, such a move is the first in Bangladesh and pharmaceuticals has been single out considering its tremendous prospect in the global market and diversification of basket as well as Bangladesh pharmaceuticals industry is the highest among the LDCs and growing with 50% annually. Bangladesh pharmaceuticals industry is one of the first growing sector in Bangladesh among the 50 LDCs. Bangladesh is the only country that is nearly self...
Words: 2796 - Pages: 12
...Corning Inc. To: From: Subject: Recommendations for the three proposals Corning Inc.’s strategy – to compete in four worldwide business sectors (communications, laboratory sciences, consumer housewares, and specialty materials) and to deliver long-range superior economic benefits to its employees, consumers, communities, and shareholders – has served the organization well for over three decades as evidenced by a transformed business portfolio, record earnings, and the emergence of a new spirit within the organization. However, due to diverse changes in trends that characterize the industry’s landscape, there is the need to come up with innovative proposals that originate from diverse business sectors. The CEO of Corning Inc. hopes that these proposals would aid in the company’s continual growth. These proposals deal with (a) the laboratory sciences, (b) communication (fiber optics), and (c), the television glass division. The opinions given are a result of a comprehensive deduction of the Porter’s Five Forces model so as to identify the best paths of actions to achieve a proper competitive advantage in the industry. For the first proposal, I think it is vital that Corning maintains its relationship with Ciba Geigy. Ciba Geigy has portrayed a strong commitment to the partnership’s success as evidenced by its willingness to preserve with significantly low returns over the next few years as the venture continues to grow. Furthermore, it has a good strategic fit with Corning Inc...
Words: 623 - Pages: 3
...Q1 Using Pestel Analysis, identify what environmental factors are affecting big pharmaceutical companies strategically? Introduction Johnson and Scholes (2002) p10 define strategy as “the direction and scope of an organisation over the long term, which achieves advantage for the organisation through its configuration of resources within a changing environment and to fulfil stakeholder expectations.” The purpose of an environmental scan is to develop a list of diverse variables from an uncertain and complex world to offer actionable responses and in so doing allow a structured framework for defensive or offensive actions. The Pharmaceutical Industry environment is an ethical drugs industry aimed at providing beneficial products and services for human consumptions as well as chemical medicaments and biotechnology. The 21st century has brought about changes within the pharmaceutical industry. The pharmaceutical industry today is highly competitive non-assembled global industry. To define the non-assembled aspect of the industry is where manufactures components parts or materials are relied on for example glass, woodwork and chemicals. It was in the sixties and seventies that the pharmaceutical industry was to expand rapidly as it was a period referred to as the spending boom. Research and development (R and D) was also a major investment and trust which was provided for Universities and education institutions. Pencillin which was the major discovery in the pharmaceutical industry...
Words: 2317 - Pages: 10
...Rina Thomas Nestle Case Study September 16, 2013 Introduction Nestle is one of the biggest food companies in the world with sales of $47 billion annually. Nestle has undergone through a huge number of transformation throughout the years. (Palmer, Dunford & Akin, 2009). Nestle manufacture product such as different cosmetics and chocolates that has been long known as a worldwide leader in its business. To increase its growth in operations, Nestle had picked up other markets for diversification other than the food industry which Nestlé’s first pick item was the cosmetic brand. But after some time, the company had acquired other products like ophthalmic and pharmaceutical. At last, for the expansion the company was required to concentrate on enhancing productivity, business expansion and financial improvement. Body 1. Did Nestle undergo either first-order and/or second-order change according to the case? Answer listing examples of types of change from the above story. In the case study, Nestle went through major first order change. One of the first-order changes that occurred was in the 1900’s when Nestle changed its approach to global expansion by acquiring subsidies in other countries. Prior to that, Nestle only operated with sales agents to buy their products out of Switzerland, so they changed their international strategy maintaining the company’s goals and the organizational mission. During the First World War, this had increased the demand...
Words: 1158 - Pages: 5
...HR Practices in Novartis Bangladesh Contents Executive Summary .................................................................................................................................... 2 Introduction ................................................................................................................................................. 3 Company Background .............................................................................................................................. 3 Mission...................................................................................................................................................... 4 Vision ........................................................................................................................................................ 4 Methodology ................................................................................................................................................ 4 Recruitment ................................................................................................................................................. 5 Selection ....................................................................................................................................................... 6 Basic stages of selection ........................................................................................................................... 6 Tests Measures ...........
Words: 2879 - Pages: 12
...Novartis V. Union of India & Others – A Landmark Judgement on Indian Patent Law & Pharmaceutical Industry: A Report The Supreme Court judement on the Novartis v. Union of India & Others is a landmark decision on the issue of pharmaceutical patent in India. The decision taken after a seven year long litigation fought by pharmaceutical major Novartis is based on a case pertaining to grant of Indian patent on a compound called Imatinib Mesylate in Beta Crystalline Form (referred as Imatinib hereinafter as convenience of brevity). The Supreme Court decided that Imatinib, the substance for which Novartis sought patent does not qualify the test of invention as laid down in section 2(1)(j), section 2(1)(ja) and the test of efficacy under section 3(d) of the Indian Patent Act, 1970. The decision generated widespread discussion and debate on affordability of life saving drugs in India for public good and impact on R&D for further innovation in pharmaceutical industry. The report covers following contents. 1. Background of the Novartis Case ❖ Fact of the case ❖ Underlying legal provisions 2. Overview of patent law in India with special focus on pharmaceutical industry 3. Supreme Court Decision in Novartis Case 4. Impact of the Supreme Court Judgement ❖ On affordability of life saving drugs ❖ On innovation for future improvement and development ❖ Overall impact on pharmaceutical industry...
Words: 2339 - Pages: 10
...Novartis: Facts 1. Jurg Zimmerman had invented a number of derivatives of N-Phenyl-2-pyrimidine-amine including Imatinab. 2. These derivatives had valuable anti-tumor properties and hence could be used in pharmaceutical compositions for the treatment of human beings against cancer. 3. These derivatives had been granted patent in both the US and Europe. Beginning with Imatinab in its base form. 4. Novartis claims to have developed Beta Crystalline form of Imatinab in a two-stage process and a direct process, with obtaining Imatinab Mesylate in amorphous form as an output in the stage one of the two-stage process. 5. An application was filed for the patent of the beta crystalline form of Imatinab Mesylate in India claiming that the newly invented form had more beneficial flow properties, thermodynamic stability and a lower hygroscopicity than the original Imatinab. 6. Further, they claimed it has better storage properties and that it was easier to process than the Imatinab in basic form. 7. However it was also claimed in the application for patent that all the inhibitory and pharmacological effects of the beta crystalline form of Imatinab Mesylate were also found in the base form of the compound. Novartis: Law Points and Development of the Case 1. When the application was filed for patent in the year 1995,the patent laws in India were under transition phase and as a result the application held in a dormant mode. 2. Later in March 2002, the applicant makes another...
Words: 1511 - Pages: 7
